A meta-analysis of 758 R/R ALL patients who received CD19 CAR-T cell therapy indicated that CAR-T cells bridged to allo-HSCT were associated with a lower CIR (HR 0.40, p < 0.001) and better DFS (HR 0.20, p < 0.001) and OS (HR 0.37, p = 0.003) than CAR-T cells alone [39]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.